Combination prostate-specific membrane antigen-targeted radiopharmaceutical therapy in metastatic prostate cancer
{{output}}
Radiopharmaceutical therapy is emerging rapidly as an effective and safe pillar in cancer management. The regulatory approvals for 177Lu-PSMA-617 radiopharmaceutical therapy in both the pre- and post-chemotherapy metastatic castration resistant prostate cancer... ...
